Beijing Kawin Technology Share-holding Co Ltd Asset Resilience Ratio
Beijing Kawin Technology Share-holding Co Ltd asset resilience ratio. Beijing Kawin Technology Share-holding Co Ltd (688687) has an Asset Resilience Ratio of 12.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688687 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beijing Kawin Technology Share-holding Co Ltd (2021–2025)
Asset resilience ratio of Beijing Kawin Technology Share-holding Co Ltd from 2021 to 2025. This chart shows how Beijing Kawin Technology Share-holding Co Ltd's Asset Resilience Ratio has changed over time. See how much free cash does Beijing Kawin Technology Share-holding C generate to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Beijing Kawin Technology Share-holding Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688687 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥337.92 Million | 12.53% |
| Total Liquid Assets | CN¥337.92 Million | 12.53% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Kawin Technology Share-holding Co Ltd has 12.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Kawin Technology Share-holding Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Kawin Technology Share-holding Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Beijing Kawin Technology Share-holding Co Ltd Asset Resilience Ratio by Year (2021–2025)
Beijing Kawin Technology Share-holding Co Ltd asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Beijing Kawin Technology Share-holding Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.29% | CN¥287.50 Million ≈ $42.07 Million |
CN¥2.79 Billion ≈ $408.72 Million |
-3.12pp |
| 2024-12-31 | 13.41% | CN¥350.87 Million ≈ $51.34 Million |
CN¥2.62 Billion ≈ $382.75 Million |
-1.51pp |
| 2023-12-31 | 14.92% | CN¥365.33 Million ≈ $53.46 Million |
CN¥2.45 Billion ≈ $358.25 Million |
-8.21pp |
| 2022-12-31 | 23.13% | CN¥511.12 Million ≈ $74.79 Million |
CN¥2.21 Billion ≈ $323.35 Million |
+19.46pp |
| 2021-12-31 | 3.67% | CN¥80.00 Million ≈ $11.71 Million |
CN¥2.18 Billion ≈ $318.67 Million |
-- |
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more